Bayer oral anticoagulant Xarelto has gained positive common drug review (CDR) recommendation from the Canadian Agency for Drugs and Technologies in Health for the prevention of stroke and systemic embolism in atrial fibrillation (AF) patients.
Xarelto (rivaroxaban tablet) is indicated for the prevention of stroke and systemic embolism in patients with AF, in whom anticoagulation is appropriate.
Bayer Corporate Affairs head Doug Grant said, "As a company with a significant and long-standing focus on anticoagulation, we are pleased to see CADTH's recommendation that provinces reimburse a once-daily treatment that does not require routine blood tests or dose adjustments for AF patients at risk of stroke."
The recommendation is based on evaluation of cost-effectiveness and clinical evidence in the Phase III ROCKET AF study that compared once-daily Xarelto with warfarin.
